questionsmedicales.fr
Phénomènes génétiques
Structures génétiques
Génome
Composants de génome
Gènes
Gènes régulateurs
Gènes switch
Gènes switch : Questions médicales fréquentes
Termes MeSH sélectionnés :
Programmed Cell Death 1 Receptor
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Gènes switch : Questions médicales les plus fréquentes",
"headline": "Gènes switch : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Gènes switch : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-19",
"dateModified": "2025-03-14",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Gènes switch"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Gènes régulateurs",
"url": "https://questionsmedicales.fr/mesh/D005809",
"about": {
"@type": "MedicalCondition",
"name": "Gènes régulateurs",
"code": {
"@type": "MedicalCode",
"code": "D005809",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.360.340.024.340.425"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Gènes switch",
"alternateName": "Genes, Switch",
"code": {
"@type": "MedicalCode",
"code": "D005812",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Martin Fussenegger",
"url": "https://questionsmedicales.fr/author/Martin%20Fussenegger",
"affiliation": {
"@type": "Organization",
"name": "ETH Zürich, Department of Biosystems Science and Engineering, Mattenstrasse 26, 4058, Basel, Switzerland; University of Basel, Faculty of Life Science, Basel, Switzerland. Electronic address: fussenegger@bsse.ethz.ch."
}
},
{
"@type": "Person",
"name": "Ana Palma Teixeira",
"url": "https://questionsmedicales.fr/author/Ana%20Palma%20Teixeira",
"affiliation": {
"@type": "Organization",
"name": "ETH Zürich, Department of Biosystems Science and Engineering, Mattenstrasse 26, 4058, Basel, Switzerland."
}
},
{
"@type": "Person",
"name": "Jin Wang",
"url": "https://questionsmedicales.fr/author/Jin%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, Physics and Applied Mathematics, State University of New York at Stony Brook, Stony Brook, New York 11794, USA."
}
},
{
"@type": "Person",
"name": "Jörg S Hartig",
"url": "https://questionsmedicales.fr/author/J%C3%B6rg%20S%20Hartig",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, University of Konstanz, Universitätsstraße 10, 78457 Konstanz, Germany; Konstanz Research School Chemical Biology (KoRS-CB), University of Konstanz, Universitätsstraße 10, 78457 Konstanz, Germany. Electronic address: joerg.hartig@uni-konstanz.de."
}
},
{
"@type": "Person",
"name": "Omer Gokcumen",
"url": "https://questionsmedicales.fr/author/Omer%20Gokcumen",
"affiliation": {
"@type": "Organization",
"name": ""
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Programmed cell death-1 blockade therapy in melanoma: Resistance mechanisms and combination strategies.",
"datePublished": "2023-01-24",
"url": "https://questionsmedicales.fr/article/36645031",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/exd.14750"
}
},
{
"@type": "ScholarlyArticle",
"name": "MicroRNAs Targeting Programmed Cell Death Protein 1 (PD-1) Promote Natural Killer Cell Exhaustion in Rheumatoid Arthritis.",
"datePublished": "2022-12-24",
"url": "https://questionsmedicales.fr/article/36640056",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.18502/ijaai.v21i6.11524"
}
},
{
"@type": "ScholarlyArticle",
"name": "Differential expression of programmed death 1 (PD-1) on various immune cells and its role in human leprosy.",
"datePublished": "2023-04-21",
"url": "https://questionsmedicales.fr/article/37153623",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2023.1138145"
}
},
{
"@type": "ScholarlyArticle",
"name": "A High Programmed Cell Death Protein 1 Hormone Receptor Score on Skin Biopsy is Associated with Sézary Syndrome Diagnosis: A Study of 91 Patients with Erythroderma.",
"datePublished": "2022-09-06",
"url": "https://questionsmedicales.fr/article/35758515",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2340/actadv.v102.1062"
}
},
{
"@type": "ScholarlyArticle",
"name": "Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.",
"datePublished": "2022-11-25",
"url": "https://questionsmedicales.fr/article/36442821",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.actbio.2022.11.043"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes génétiques",
"item": "https://questionsmedicales.fr/mesh/D055614"
},
{
"@type": "ListItem",
"position": 3,
"name": "Structures génétiques",
"item": "https://questionsmedicales.fr/mesh/D040342"
},
{
"@type": "ListItem",
"position": 4,
"name": "Génome",
"item": "https://questionsmedicales.fr/mesh/D016678"
},
{
"@type": "ListItem",
"position": 5,
"name": "Composants de génome",
"item": "https://questionsmedicales.fr/mesh/D040481"
},
{
"@type": "ListItem",
"position": 6,
"name": "Gènes",
"item": "https://questionsmedicales.fr/mesh/D005796"
},
{
"@type": "ListItem",
"position": 7,
"name": "Gènes régulateurs",
"item": "https://questionsmedicales.fr/mesh/D005809"
},
{
"@type": "ListItem",
"position": 8,
"name": "Gènes switch",
"item": "https://questionsmedicales.fr/mesh/D005812"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Gènes switch - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Gènes switch",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Gènes switch",
"description": "Comment identifier un gène switch ?\nQuels tests sont utilisés pour les gènes switch ?\nLes gènes switch sont-ils visibles sur une analyse génétique ?\nPeut-on détecter des mutations dans les gènes switch ?\nQuels marqueurs sont associés aux gènes switch ?",
"url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Gènes switch",
"description": "Quels symptômes sont liés aux gènes switch ?\nLes gènes switch affectent-ils le développement ?\nPeut-on observer des anomalies dues aux gènes switch ?\nLes gènes switch influencent-ils le comportement ?\nY a-t-il des symptômes neurologiques associés ?",
"url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Gènes switch",
"description": "Peut-on prévenir les maladies liées aux gènes switch ?\nQuels modes de vie peuvent aider à prévenir ces maladies ?\nLes conseils génétiques sont-ils utiles ?\nY a-t-il des vaccins pour prévenir les effets des gènes switch ?\nComment le suivi médical contribue-t-il à la prévention ?",
"url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Gènes switch",
"description": "Comment traiter les dysfonctionnements des gènes switch ?\nLes traitements sont-ils personnalisés ?\nY a-t-il des essais cliniques pour ces traitements ?\nLes traitements sont-ils efficaces ?\nQuels effets secondaires peuvent survenir ?",
"url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Gènes switch",
"description": "Quelles complications peuvent survenir avec les gènes switch ?\nLes gènes switch peuvent-ils causer des maladies héréditaires ?\nY a-t-il des risques de transmission familiale ?\nLes complications sont-elles réversibles ?\nComment les gènes switch affectent-ils la longévité ?",
"url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Gènes switch",
"description": "Quels facteurs de risque sont associés aux gènes switch ?\nL'âge est-il un facteur de risque ?\nLe mode de vie influence-t-il les gènes switch ?\nLes facteurs génétiques jouent-ils un rôle ?\nLes infections peuvent-elles affecter les gènes switch ?",
"url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier un gène switch ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'identification se fait par des techniques comme le séquençage et l'analyse d'expression génique."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour les gènes switch ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de PCR et des analyses de microarray sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Les gènes switch sont-ils visibles sur une analyse génétique ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être détectés indirectement par l'expression des gènes qu'ils régulent."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des mutations dans les gènes switch ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations peuvent être identifiées par séquençage ciblé."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont associés aux gènes switch ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs épigénétiques comme les méthylations peuvent indiquer leur activité."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés aux gènes switch ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes varient selon les gènes régulés, incluant des troubles métaboliques."
}
},
{
"@type": "Question",
"name": "Les gènes switch affectent-ils le développement ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils jouent un rôle crucial dans le développement embryonnaire et cellulaire."
}
},
{
"@type": "Question",
"name": "Peut-on observer des anomalies dues aux gènes switch ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies peuvent se manifester par des malformations congénitales ou des cancers."
}
},
{
"@type": "Question",
"name": "Les gènes switch influencent-ils le comportement ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains gènes switch peuvent affecter des traits comportementaux et cognitifs."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques associés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines dysrégulations peuvent entraîner des troubles neurologiques variés."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les maladies liées aux gènes switch ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par le dépistage génétique et des interventions précoces."
}
},
{
"@type": "Question",
"name": "Quels modes de vie peuvent aider à prévenir ces maladies ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, est bénéfique."
}
},
{
"@type": "Question",
"name": "Les conseils génétiques sont-ils utiles ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les conseils génétiques aident à évaluer les risques et à planifier des actions préventives."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins pour prévenir les effets des gènes switch ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiques pour les gènes switch."
}
},
{
"@type": "Question",
"name": "Comment le suivi médical contribue-t-il à la prévention ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier permet de détecter précocement des anomalies et d'intervenir rapidement."
}
},
{
"@type": "Question",
"name": "Comment traiter les dysfonctionnements des gènes switch ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies géniques et des médicaments ciblés peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction du profil génétique du patient."
}
},
{
"@type": "Question",
"name": "Y a-t-il des essais cliniques pour ces traitements ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, de nombreux essais cliniques explorent des thérapies pour les gènes switch."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité varie selon le type de gène switch et la pathologie associée."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires peuvent survenir ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets secondaires peuvent inclure des réactions immunitaires ou des complications."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les gènes switch ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des cancers, des troubles métaboliques et des malformations."
}
},
{
"@type": "Question",
"name": "Les gènes switch peuvent-ils causer des maladies héréditaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains gènes switch sont impliqués dans des maladies héréditaires complexes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de transmission familiale ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les gènes switch peuvent être transmis et affecter plusieurs membres d'une famille."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles."
}
},
{
"@type": "Question",
"name": "Comment les gènes switch affectent-ils la longévité ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dysfonctionnements peuvent réduire l'espérance de vie en augmentant le risque de maladies."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés aux gènes switch ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs environnementaux, génétiques et comportementaux peuvent influencer leur activité."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge peut affecter l'expression des gènes switch et le risque de maladies."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il les gènes switch ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes comme le tabagisme ou l'alimentation peuvent moduler leur activité."
}
},
{
"@type": "Question",
"name": "Les facteurs génétiques jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des variations génétiques peuvent prédisposer à des dysfonctionnements des gènes switch."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles affecter les gènes switch ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections peuvent altérer l'expression des gènes switch et provoquer des maladies."
}
}
]
}
]
}
Melanoma is a highly aggressive tumor derived from melanocytes. In recent years, the incidence and mortality of melanoma have gradually increased, seriously threatening human health. Classic treatment...
Natural killer (NK) cells play a role in the pathogenesis of rheumatoid arthritis (RA). Upregulated levels of programmed cell death protein 1 (PD-1) is a sign of exhausted NK cells that could be regul...
Leprosy is a chronic bacterial disease caused by...
Erythroderma is challenging to diagnose. The aim of this single-centre retrospective study was to identify factors that can be used to improve the diagnosis of erythroderma. Among 91 patients with ery...
Immune checkpoint blockade therapy targeting programmed death-1 (PD-1) or its major ligand programmed death-ligand 1 (PD-L1) has achieved remarkable success in the treatment of several tumors, includi...
The immune system uses various immune checkpoint axes to adjust responses, support homeostasis, and deter self-reactivity and autoimmunity. Nevertheless, non-small-cell lung carcinoma (NSCLC) can use ...
Pembrolizumab or nivolumab plus chemotherapy was approved as a first-line treatment for high programmed cell death ligand 1 (PD-L1)-expressing esophageal squamous cell carcinoma (ESCC) by the European...
Post hoc analysis of the Chinese JUPITER-06 study focusing on efficacy stratified by PD-L1 tumor proportion score (TPS; using JS311 antibody) was conducted. Electronic databases were searched to ident...
The post hoc analysis of JUPITER-06 showed more prominent clinical benefit with PD-1 antibody plus chemotherapy than with chemotherapy alone in both the high and low PD-L1-expressing subgroups. Five r...
This study provided novel evidence supporting the superiority of PD-1 antibody plus chemotherapy to chemotherapy alone in patients with advanced ESCC with low PD-L1 expression. Further studies of pred...
Major depression (MD) may be associated with inflammation and immunity. PD-1 (programmed death-1), PD-L1 (programmed death-ligand 1) and PD-L2 (programmed death-ligand 2) are among the inhibitory immu...
During a period of 2 years, patients with MD and healthy controls were recruited from a medical centre in this study. The diagnosis of MD was established according to the DSM-5 criteria. The severity ...
A total of 54 patients with MD and 38 healthy controls were recruited. According to the analyses, there is a significantly higher PD-L2 level in MD than in healthy controls and lower PD-1 level after ...
It was found that PD-1 pathway might play an important role in MD. We need a large sample to prove these results in the future....
Tumor-infiltrating lymphocytes are detectable in up to 75% of triple-negative breast cancer. The composition of these infiltrates may influence prognosis and is not known regarding regulatory or effec...
This was a retrospective observational study. Clinical and pathological data from 38 triple-negative breast cancer patients treated with neoadjuvant chemotherapy at the University Hospital (HUCFF/UFRJ...
Statistically significant changes in stromal tumor-infiltrating lymphocyte categories were observed before and post-neoadjuvant chemotherapy, with 32% of intermediate cases becoming high. The correlat...
In this study, we observed that chemotherapy significantly increases stromal tumor-infiltrating lymphocytes, CD8 T cells, as well as CD8/FoxP3 ratio. Most importantly, programmed cell death protein 1 ...
Melanoma is widely treated with programmed cell death-1 (PD-1) inhibitors. As part of their anti-tumor immunity effect, they increase the susceptibility to cutaneous immune-related adverse events (cIR...